Steroid 5a-reductase is a NADPH-dependent enzyme responsible for the reduction of testosterone (T) 1 into the more potent androgen (DHT) 2, Fig. 1. 1) This enzyme is located in the androgen-dependent tissue such as the prostate, seminal vesicles, epididymis and other reproductive tissues.
It has been determined that DHT 2 interacts more efficiently with the androgen receptors than its precursor T 1 2) and it has been implicated in the pathogenesis of prostate cancer, benign prostatic hyperplasia (BPH), acne and male pattern baldness. 2, 3) This fact indicates that both the 5a-reductase enzyme and DHT 2 play important physiological and pathological roles in human males. Therefore, the inhibition of DHT formation by the 5a-reductase enzyme is a logical treatment for androgen dependent afflictions. 4) Recently, several new inhibitors of 5a-reductase were described as potential clinical candidates for the treatment of androgen-dependent disorders. These compounds (Fig. 1 ) include finasteride 3, 5) turosteride 4 6) and dutasteride 5. 7) Finasteride 3, a 4-azasteroid is the first 5a-reductase inhibitor approved in the U.S.A. for the treatment of BPH. In humans, finasteride decreases prostatic DHT levels by 70-90% and reduces prostate size, while T tissue levels remain constant. 5) The use of finasteride demonstrated a sustained improvement in the treatment of androgen dependent diseases, and it also reduces the prostate specific antigen (PSA) levels. 5) Several years ago, we synthesized several new 17a-acyloyloxypregnadiene and pregnatrienes derivatives that showed a high inhibitory effect for the enzyme 5a-reductase as well as high affinity for androgen receptors. 8, 9) In view of the fact that endocyclic dienes and trienes described in these references 8, 9) showed high biological activity, in this paper we report the synthesis and pharmacological evaluation of five (12-16, Fig. 3 ) new similar compounds, based on the progesterone skeleton, as inhibitors for the hamster and human 5a-reductase enzyme. The in vitro effect was assayed in human prostate, 10) and the in vivo effects were determined in the prostate of gonadectomized male hamsters. 11, 12) (Fig. 3) were prepared from the commercially available 16-dehydropregnenolone acetate 6 (Fig. 2) . Esterification of the hydroxyl group in 12 with trifluoroacetic anhydride, the corresponding carboxylic acid and PTSA yielded the desired esters 13-16. Treatment of 14 with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) in dioxane afforded the trienedione 16.
Results

Synthesis of New Compounds Compounds 12-16
In Vivo Experiments After castration, the weight of the In this study we report the synthesis and pharmacological evaluation of four new progesterone derivatives; 17a a-hydroxy-16b b-methylpregna-4,6-diene-3,20-dione 12, 17a a-cyclopropylcarbonyloxy-16b b-methylpregna-4,6-diene-3,20-dione 13, 17a a-cyclobutylcarbonyloxy-16b b-methylpregna-4,6-diene-3,20-dione 14, 17a a-acetoxy-16b bmethylpregna-4,6-diene-3,20-dione 15 and the pregnatriene compound 17a a-cyclobutylcarbonyloxy-16b b-methylpregna-1,4,6-triene-3,20-dione 16. The pharmacological effect of these compounds was determined in vivo as well as in vitro. The evaluation in vivo was carried out on gonadectomized male hamsters that were injected subcutaneously daily with testosterone (T) and/or finasteride, or with the novel compounds. At the end of the treatments the animals were sacrificed and the prostates were weighed. It was observed that when testosterone (T) and finasteride or compounds 12-16 were injected together, the weight of the prostate decreased significantly as compared to that of the testosterone-treated animals. The 5a a-reductase inhibitory activity was evaluated in vitro using human prostate homogenates. These experiments showed the following IC 50 values: compound 12 (alcohol at C-17) 1 It is evident from these data that when the size of the substituent at C-17 is decreased, the 5a a-reductase inhibitory activity increases. Apparently, in this biological model, the 5a a-reductase inhibitory activity depends upon the steric effect of the substituent at C-17. However, the free alcohol 12 showed much lower 5a a-reductase inhibitory activity.
male hamster prostate decreased (pϽ0.005) compared to that of the normal glands. Treatment with vehicle alone did not change this condition, whereas s.c. injections of 200 mg of T for 6 d significantly increased (pϽ0.005) the weight of this gland in castrated male hamsters (Table 1) . When testosterone (T) and finasteride or compounds 12-16 were injected together, the weight of the prostate decreased (pϽ0.005) as compared to that of testosterone-treated animals (Table 1) .
In Vitro Experiments The in vitro biological activity of compounds 12-16 was determined in human prostate gland which was homogenized and centrifuged to obtain the prostatic enzyme fraction. The activity of human 5a-reductase was assessed by incubating the enzymatic fractions with 2 nM [ 3 H]T. The dichloromethane extracts from human prostates were subjected to TLC analysis. The zone corresponding to the DHT standard (Rf value of 0.67) of the experimental chromatogram was cut off, soaked in Ultima Gold, and the radioactivity determined. This result was considered to be 100% of the activity of 5a-reductase for the development of inhibition plots. Unmodified [ ductase activity by 50% (IC 50 ) were determined from the inhibition curves using different concentrations of the steroids, and are shown in (Table 2) .
Discussion
This study reports the synthesis and pharmacological evaluation of four pregnadiene derivatives (12-15) and one pregnatriene compound 16. As can be seen in Table 1 , all derivatives decreased the weight of the prostate gland as compared to that of the testosterone treated animals. Compound 14 has similar antiandrogenic activity (wt of the prostate gland 41.8 mg) as compared to that of proscar 3 (wt of the prostate gland 39.7 mg), the drug of choice for the treatment of benign prostatic hyperplasia. The results from this study could be explained by considering the lipid solubility of these compounds. It is a well known fact that an increase in the lipid solubility of a drug is associated with higher pharmacological activity. 13) In view of the fact that compound 14 has greater lipid solubility (cyclobutyl side chain) as compared to 13 (cyclopropyl side chain) or 15 with (acetoxy side chain) explains the higher antiandrogenic activities of this compound. The free alcohol 12 showed considerably lower antiandrogenic activity as compared to the esterified compounds 13-16. Ϫ6 M. It is evident from these data that when the size of the substituent at C-17 (compound 13) is decreased, the 5a-reductase inhibitory activity increases. Apparently, in this biological model the 5a-reductase inhibitory activity depends upon the steric effect of the substituent at C-17. The free alcohol 12 showed lower 5a-reductase inhibitory activity as compared to the steroidal esters 13-16.
Experimental
Chemical and Radioactive Materials Solvents were laboratory grade or better. Melting points were determined on a Fisher Johns melting point apparatus and are uncorrected. . The tablets were crushed, extracted with chloroform, and the solvent was eliminated in a vacuum; the crude product was purified by silica gel column chromatography.
Synthesis of the Steroidal Derivatives Compounds 7-12 ( Fig. 2 ) and 13-16 (Fig. 3) were prepared from the commercially available 16-dehydropregnenolone acetate 6. Epoxidation of the double bond at C-16 in 6 with hydrogen peroxide and sodium hydroxide afforded the epoxy derivative 7. Acetylation of 7 in the usual manner yielded the acetoxy compound 8. Protection of the carbonyl group in 9 was effected with ethylene glycol, trimethyl orthoformate and p-toluenesulfonic acid (PTSA). The resulting dioxolane derivative 9 was allowed to reflux with methylmagnesium chloride in tetrahydrofuran (THF); this reaction afforded the 16-methyl substituted dioxolane derivative 10. Hydrolysis of the dioxolane ring in 10 to recover the carbonyl moiety at C-20 was carried out with PTSA in acetone, thus forming the carbonyl derivative 11. The oxidation of the hydroxyl group at C-3 in 11 was effected with lithium carbonate, lithium bromide and bromine in N,N-dimethylformamide (DMF). Esterification of the hydroxyl group in 12 was carried out with trifluoroacetic anhydride, the corresponding acyloyloxy acid and PTSA; this reaction yielded the desired esters 13-15 (Fig. 3) . Treatment of 14 with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) in dioxane afforded the trienedione compound 16.
Synthesis of the intermediates 7-12 ( Fig. 2) is given in refs. 8 and 9. The preparation of compounds 13-16 is briefly described below. The new esters 13-16 (Fig. 3) were prepared according to the following general procedure.
A solution containing steroid 12 (1 g, 2.92 mmol), PTSA (0.5 mg), trifluoroacetic anhydride (1.84 g, 8.76 mmol) and the corresponding acid (9 mmol) was stirred for 2 h at room temperature (nitrogen atmosphere). The reaction mixture was neutralized with an aqueous sodium bicarbonate solution to a pH of 7, then diluted with chloroform (10 ml). The organic phase was separated, washed with water and drier over anhydrous sodium sulfate; the solvent was eliminated in a vacuum. The crude product was purified by silica gel column chromatography. Hexane-ethyl acetate (8 : 2) eluted the pure ester.
17a -Cyclopropylcarbonyloxy-16b -methylpregna-4,6-diene-3,20-dione 13: Yield 75%, mp 192-193°C. UV (nm) 283 (eϭ22900). IR (KBr) cm 
. 17a -Cyclobutylcarbonyloxy-16b -methylpregna-1-4,6-triene-3,20-dione 16 A solution of steroid 14 (1 g, 2.36 mmol) and DDQ (2.13 g, 9.43 mmol) in dioxane (100 ml) was allowed to reflux for 2 d. Upon cooling, the precipitated 2,3-dichloro-5,6-dicyanohydroquinone was filtered off. To the filtrate was added 3% aqueous sodium hydroxide solution (100 ml) and chloroform (100 ml); the mixture was stirred for 5 min. The organic phase was separated, washed 3 times with 3% aqueous sodium hydroxide solution and water. It was dried over anhydrous sodium sulfate and the solvent was removed in a vacuum. The crude product was purified by silica gel column chromatography. Hexane-ethyl acetate (6 : 4) afforded 0.59 g of pure product 16. Yield 60%, mp 160-161°C. UV (nm) 222, 256, 299 (eϭ15200, 13000, 18000 respectively). IR (KBr) cm Ϫ1 1721, 1653, 1601. 
Ϫ6
They represent the concentration of the steroid that inhibits 50% of 5a-reductase activity, and were determined as described in Experimental.
(m/z) 422 (M ϩ ). Animals and Tissues Adult male golden hamsters (150-200 g) were obtained from the Metropolitan University in Xochimilco, Mexico. Gonadectomies were performed under pentobarbital anesthesia 30 d prior to the experiments, and the animals were sacrificed with CO 2 . This protocol was approved by the Institutional Care and Use Committee of the Metropolitan University of Mexico (UAM). The experiment was comprised of 9 groups of 4 animals/experiment, which were selected at random. The animals were kept in a room with controlled temperature (22°C) and light-dark periods of 12 h. Food and water were provided ad libitum.
Human prostate from a cadaver was kindly provided by Dr. Avissai Alcántara from the Department of Pathology of The General Hospital (SS) in Mexico City, and stored at Ϫ70°C. Frozen human prostate was thawed on ice and minced with scissors. Unless specified, the following procedures were carried out at 4°C. Tissue was homogenized with a tissue homogenizer (model 985-370; variable speed 5000-30000 rpm, Biospec Products, Inc.).
In Vivo Experiments For the daily subcutaneous injections, 400 mg of the steroids 12-16 were dissolved in 200 ml of sesame oil and administered for 6 d, together with 200 mg of testosterone (T). Three groups of animals were kept as a control: one was injected with 200 ml of sesame oil, the second with 200 mg of T, and the third with T plus finasteride for 6 d. After the treatment, the animals were sacrificed by CO 2 . Prostates from animals (4) of each group were dissected and weighed. Two separate experiments were performed for each group of steroid treated animals. The results (Table 1) were analyzed using one-way analysis of variance with EPISTAT software.
In Vitro Experiments Human prostate was homogenized in 2 volumes of medium A (20 mM sodium phosphate, pH 6.5, containing 0.32 M sucrose, 0.1 mM dithiothreitol Sigma-Aldrich, Inc.) with a tissue homogenizer. Homogenates were centrifuged at 1500ϫg for 20 min 10) in a SW 60 Ti rotor (Beckman Instruments, Palo Alto, Cal, U.S.A.). The pellets were separated, washed with 3 volumes of medium A and centrifuged two additional times at 440ϫg at 0°C for 10 min.
10) The washed pellets were suspended in medium A and kept at Ϫ70°C. The suspension (5 mg/ml for human prostates), determined by the Bradford method, 14) was used as a source of 5a-reductase.
Determination of 5a a-Reductase Activity The enzyme 5a-reductase was assayed as previously described.
10) The reaction mixture contained a final volume of 1 ml: 1 mM dithiothreitol, sodium phosphate buffer (40 mM), at pH 6.5 for human prostates, 10) 2 mM NADPH, and 2 nM [1,2,6,7-3 H]T. The reaction in duplicate was started when it was added to the enzymatic fraction (134 mg protein in a volume of 80 ml), 14) incubated at 37°C for 60 min, and stopped by mixing with 1 ml of dichloromethane; this was considered the end point. Incubation without tissue was used as a control. The fraction of dichloromethane was separated, and the extraction was repeated 4 more times. The extract was evaporated under a nitrogen stream to dryness and suspended on 50 ml of methanol that was spotted on TLC Keiselgel 60 F 254 plates. T and DHT were used as carriers, and the plates were developed in chloroform-acetoneϭ9 : 1. The plates were air-dried and the chromatography was repeated 2 more times. The steroid carriers were detected using a phosphomolibdic acid reagent and a UV lamp (254 nm). The DHT containing areas were cut off and the strips were soaked in 5 ml of Ultima Gold (Packard), then the radioactivity was counted in a scintillation counter (Packard tri-carb 2100 TR). Control incubations, chromatography separation and identification were carried out in the same way as described above except that these tubes did not contain tissue.
Determination of 50% Inhibitory Concentration of Steroids 12-16 in Human Prostatic 5a a-Reductase In order to calculate the IC 50 values (the concentration of steroids 12-16 required to inhibit 5a-reductase activity by 50%), six series of tubes containing increasing concentrations of these steroids (10 Ϫ11 -10 Ϫ3 M) were incubated in duplicate, in the presence of: 1 mM of dithiothreitol, 40 mM sodium phosphate buffer pH 6.5 for human; 2 mM NADPH, 2 nM [1,2,6,7- 3 H]T and 134 mg of protein from enzymatic fraction in a final volume of one ml. The reaction was carried out in duplicate at 37°C for 60 min, adding one ml of dichloromethane to stop the reaction. The amount of DHT formed was determined as we detailed above.
